Acute Myeloid Leukemia, in Relapse Clinical Trials

20 recruiting

Frequently Asked Questions

Common questions about Acute Myeloid Leukemia, in Relapse clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Phase 1

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Acute Myeloid LeukemiaMyeloid SarcomaAcute Myeloid Leukemia, in Relapse+7 more
Kura Oncology, Inc.420 enrolled44 locationsNCT05735184
Recruiting

Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, Refractory
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS4,000 enrolled38 locationsNCT06459024
Recruiting
Phase 1

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

Acute Myeloid LeukemiaAcute Myeloid Leukemia, in RelapseRefractory Acute Myeloid Leukemia+2 more
Memorial Sloan Kettering Cancer Center15 enrolled7 locationsNCT06017258
Recruiting
Phase 1

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia, in RelapseMyelodysplastic Syndrome With Excess Blasts+2 more
Apollo Therapeutics Ltd100 enrolled7 locationsNCT06372717
Recruiting
Phase 1

Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, RefractoryRefractory/Relapse Acute Myeloid Leukemia
Keystone Nano, Inc15 enrolled1 locationNCT04716452
Recruiting
Phase 1

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, Refractory
Memorial Sloan Kettering Cancer Center18 enrolled7 locationsNCT07011004
Recruiting
Phase 1

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, Refractory
Medical College of Wisconsin40 enrolled1 locationNCT05317403
Recruiting
Phase 1

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid LeukemiaAcute Myeloid Leukemia, in RelapseRefractory Acute Myeloid Leukemia
Terrence J Bradley, MD18 enrolled1 locationNCT05597306
Recruiting
Phase 1

PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

Acute Myeloid LeukemiaAcute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, Refractory
Seattle Children's Hospital18 enrolled1 locationNCT05105152
Recruiting
Phase 1

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

MDSAcute Myeloid Leukemia, in Relapse
Marker Therapeutics, Inc.40 enrolled3 locationsNCT06552416
Recruiting
Phase 1Phase 2

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, RefractoryMDS (Myelodysplastic Syndrome)
ARCE Therapeutics, Inc.49 enrolled3 locationsNCT06680752
Recruiting
Phase 1Phase 2

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, RefractoryMyelodysplastic Syndrome/Acute Myeloid Leukemia
AB Science78 enrolled10 locationsNCT05211570
Recruiting
Phase 1

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, Refractory
AvenCell Europe GmbH80 enrolled11 locationsNCT05949125
Recruiting

Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways

Acute Myeloid Leukemia, in Relapse
Ciceri Fabio500 enrolled1 locationNCT05124288
Recruiting
Early Phase 1

Off-the-shelf CD123 CAR-NK for R/R AML

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, Refractory
Peking University People's Hospital12 enrolled1 locationNCT06201247
Recruiting
Phase 1

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, Refractory
Bio-Path Holdings, Inc.48 enrolled4 locationsNCT05190471
Recruiting
Phase 2

Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen

Chronic Myeloid LeukemiaMyelodysplastic SyndromesMyeloproliferative Neoplasm+1 more
St. Petersburg State Pavlov Medical University88 enrolled1 locationNCT06532084
Recruiting
Phase 1

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, Refractory
Oryzon Genomics S.A.50 enrolled13 locationsNCT05546580
Recruiting
Phase 1Phase 2

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, Refractory
Xuzhou Medical University20 enrolled1 locationNCT06125652
Recruiting
Phase 1

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, Refractory
University Hospital, Antwerp10 enrolled2 locationsNCT05506332